Shares of Ranbaxy Laboratories will stop trading on BSE and NSE with effect from April 6 onwards as the company is merging with Sun Pharmaceutical Industries in a $4 billion deal.
Sun Pharma would be delisting Ranbaxy from the exchanges.
It has consummated the merger of Ranbaxy following receipt of requisite approvals.
In separate circulars on Wednesday, leading bourses BSE and NSE said suspension in trading of the scrip would be effective from "April 6, 2015 (ie closing hours of trading on April 1, 2015)," NSE said in a circular.
Sun Pharma has fixed April 7 as the record date for determining the entitlement of Ranbaxy shareholders to the equity shares of the former.
Upon the amalgamation scheme becoming effective, Sun Pharma would allot shares to all the shareholders of Ranbaxy in the exchange ratio of "0.80 equity share of Re 1 each of Sun Pharmaceutical Industries for every 1 equity share of Rs 5 each held in Ranbaxy Laboratories Ltd," BSE said in its circular.
In April, 2014, Sun Pharma had announced it would acquire Ranbaxy in an all-stock transaction worth $4 billion that includes $800 million debt.
The merger would create India's largest and the world's fifth-largest drug maker.
Copyright©2021 Living Media India Limited. For reprint rights: Syndications Today